Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01256268 · ClinicalTrials.gov registry record · Phase 1
Carboplatin/Taxol/Ridaforolimus in Endometrial, Ovarian and Solids
A Phase 1 study, sponsored by H. Lee Moffitt Cancer Center and Research Institute.
- Completed
- Registry status
- Phase 1
- Development phase
- 24
- Enrollment target
NCT01256268 is a Phase 1 study that has completed, run by H. Lee Moffitt Cancer Center and Research Institute. The registered enrollment target is 24 participants.
The verdict
NCT01256268, a Phase 1 study, has completed, sponsored by H. Lee Moffitt Cancer Center and Research Institute.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 24 participants
- Enrollment target
Study Summary
The purpose of this study is to: * Test the safety of a new investigational drug called MK-8669 (ridaforolimus) * Determine the maximum tolerated dose of MK-8669 * Determine the effectiveness of the maximum tolerated dose of MK-8669
Interventions
- DRUG Paclitaxel
- DRUG carboplatin
- DRUG Ridaforolimus
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2011-06-13 |
| Est. Completion | 2017-08-03 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01256268
The ClinicalTrials.gov registry entry for NCT01256268 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 24 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is H. Lee Moffitt Cancer Center and Research Institute, which has 502 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Paclitaxel is the first listed.
NCT01256268 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01256268 about?
NCT01256268 is a clinical study titled "Carboplatin/Taxol/Ridaforolimus in Endometrial, Ovarian and Solids". The purpose of this study is to: * Test the safety of a new investigational drug called MK-8669 (ridaforolimus) * Determine the maximum tolerated dose of MK-8669 * Determine the effectiveness of the maximum tolerated dose of MK-8669
What is the current status of trial NCT01256268?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 24 participants. The study started on 2011-06-13. Estimated completion is 2017-08-03.
What interventions are being tested in trial NCT01256268?
The interventions under investigation include: Paclitaxel (DRUG), carboplatin (DRUG), Ridaforolimus (DRUG).
Who is sponsoring clinical trial NCT01256268?
This trial is sponsored by H. Lee Moffitt Cancer Center and Research Institute, which has 502 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.